Sevan Kaloustian, Vice President at Johnson & Johnson Innovative Medicine, shared a post on LinkedIn:
“Over the past few years we brought incredible data for patients with hematologic malignancies.
This year at European Hematology Association (EHA) we will continue bringing forward incredible clinical data from our JNJ innovative medicines.”
Other articles featuring Dr. Kaloustian on OncoDaily.